Icon
Impact Analyses: Granules India Ltd, Gagillapur receives 6 FDA observations

Granules India Ltd. announced that, its Gagillapur facility (Gagillapur Village, Dundigal-Gandimaisamma Mandal, Medchal-Malkajgiri District, Telangana, India) received ‘Form 483’ with six observations. Granules India manufactures 21 of the total 54 formulation products manufactured for the US market. This facility manufactures Oral Solids. 

Your web browser doesn't have a PDF plugin. Instead you can click here to download the PDF file.